Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment
Colon cancer is one of the most life-threatening cancers with high incidence and mortality rates. Current first-line treatments are ineffective and possess many unwanted effects. The off-label use of paclitaxel encapsulated in nanoparticles proves an innovative approach. In this study, we reported novel paclitaxel loaded EDC-crosslinked fibroin nanoparticles (PTX-FNPs) for anticancer purpose. The particles were formulated using desolvation method and the physicochemical properties were controlled favorably, including the particle size (300–500 nm), zeta potential (− 15 to + 30 mV), drug entrapment efficiency (75–100%), crystallinity, drug solubility (1- to 10-fold increase), dissolution profiles, stability (> 24 h in intravenous diluent and > 6 months storage at 4 °C). In in vitro study, all formulations showed no toxicity on the red blood cells, whereas retained the paclitaxel cytotoxicity on MCF-7 breast cancer and Caco-2 colon cancer cells. Interestingly, PTX-FNPs can be uptaken rapidly by the Caco-2 cells, consequently increased paclitaxel potency up to 10-fold compared to the free drug.
KeywordsPaclitaxel Colon Cancer Fibroin Nanoparticles EDC Crosslinked
Duy Toan Pham thanks Naresuan University ASEAN Scholarship, the RGJ Ph.D. Grant, the Boosting Research Potential for NU Students (Batch 4) Fellowship, and the Naresuan University Scholarship for Oral Presentation for funding his doctoral study. We also want to thank the staff of the Faculty of Pharmaceutical Sciences, Naresuan University, for their kind guidance. Thank you, mom, dad, and Phung for everything.
This study received financial support from the Thailand Research Fund (TRF) under the Royal Golden Jubilee (RGJ) Ph.D. Grant No. PHD/0234/2560 RGJ and the Naresuan University Grant No. R2561B009.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, et al. Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial. Cancer Chemother Pharmacol. 2017;79(1):9–16. https://doi.org/10.1007/s00280-016-3193-5.CrossRefPubMedGoogle Scholar
- 12.Sheppard BC, Rutten MJ, Meichsner CL, Bacon KD, Leonetti PO, Land J, et al. Effects of paclitaxel on the growth of normal, polyposis, and cancerous human colonic epithelial cells. Cancer. 1999;85(7):1454–64. https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7<1454::AID-CNCR5>3.0.CO;2-%23.CrossRefPubMedGoogle Scholar
- 15.Forrest ML, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res. 2008;25(1):194–206. https://doi.org/10.1007/s11095-007-9451-9.CrossRefPubMedGoogle Scholar
- 16.Kim K, Kim JH, Park H, Kim YS, Park K, Nam H, et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release. 2010;146(2):219–27. https://doi.org/10.1016/j.jconrel.2010.04.004.CrossRefPubMedGoogle Scholar
- 18.Lee MK, Lim SJ, Kim CK. Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007;28(12):2137–46. https://doi.org/10.1016/j.biomaterials.2007.01.014.CrossRefPubMedGoogle Scholar
- 21.Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, et al. Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials. 2010;31(28):7355–63. https://doi.org/10.1016/j.biomaterials.2010.05.061.CrossRefPubMedGoogle Scholar
- 32.Israelachvili J. Intermolecular & Surface Forces. 3rd ed. Cambridge: London Academic Press; 1985.Google Scholar
- 34.Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997;94(8):4028–33. https://doi.org/10.1073/pnas.94.8.4028.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Bray LJ, Suzuki S, Harkin DG, Chirila TV. Incorporation of exogenous RGD peptide and inter-species blending as strategies for enhancing human corneal limbar epithelial cell growth on Bombyx mori silk fibroin membranes. J Funct Biomater. 2013;4(2):74–88. https://doi.org/10.3390/jfb4020074.CrossRefPubMedPubMedCentralGoogle Scholar